Clinical Value of Using Heart Rate Variability Biofeedback Before Elective CT Coronary Angiography to Reduce Heart Rate and the Need for Beta-Blockers

IF 2.2 3区心理学 Q2 PSYCHOLOGY, CLINICAL

Applied Psychophysiology and Biofeedback Pub Date : 2023-06-21 DOI:10.1007/s10484-023-09590-6

Patrick Langguth, Carmen Wolf, Sam Sedaghat, Monika Huhndorf, Johanne Frank, Marcus Both, Olav Jansen, Mona Salehi Ravesh, Annett Lebenatus

{"title":"Clinical Value of Using Heart Rate Variability Biofeedback Before Elective CT Coronary Angiography to Reduce Heart Rate and the Need for Beta-Blockers","authors":"Patrick Langguth, Carmen Wolf, Sam Sedaghat, Monika Huhndorf, Johanne Frank, Marcus Both, Olav Jansen, Mona Salehi Ravesh, Annett Lebenatus","doi":"10.1007/s10484-023-09590-6","DOIUrl":null,"url":null,"abstract":"<div><p>The value of biofeedback before elective coronary computed tomography angiography (CCTA) to reduce patients’ heart rates (HR) was investigated in the current work. Sixty patients who received CCTA to exclude coronary artery disease were included in our study and separated into two groups: with biofeedback (W-BF) and without biofeedback (WO-BF). The W-BF group used a biofeedback device for 15 min before CCTA. HR was determined in each patient at four measurement time points (MTP): during the pre-examination interview (MTP1), positioning on the CT patient table before CCTA (MTP2), during CCTA image acquisition (MTP3), and after completing CCTA (MTP4). If necessary, beta-blockers were administered in both groups after MTP2 until a HR of less than 65 bpm was achieved. Two board-certified radiologists subsequently assessed the image quality and analyzed the findings. Overall, the need for beta-blockers was significantly lower in patients in the W-BF group than the WO-BF group (p = 0.032). In patients with a HR of 81–90, beta-blockers were not required in four of six cases in the W-BF group, whereas in the WO-BF group all patients needed beta-blockers (p = 0.03). The amount of HR reduction between MTP1 and MTP2 was significantly higher in the W-BF compared to the WO-BF group (p = 0.028). There was no significant difference between the W-BF and WO-BF groups regarding image quality (p = 0.179). By using biofeedback prior to elective CCTA, beta-blocker use could be decreased without compromising CT image quality and analysis, especially in patients with an initial HR of 81–90 bpm.</p></div>","PeriodicalId":47506,"journal":{"name":"Applied Psychophysiology and Biofeedback","volume":"48 4","pages":"393 - 401"},"PeriodicalIF":2.2000,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s10484-023-09590-6.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Psychophysiology and Biofeedback","FirstCategoryId":"102","ListUrlMain":"https://link.springer.com/article/10.1007/s10484-023-09590-6","RegionNum":3,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}

引用次数: 0

Abstract

The value of biofeedback before elective coronary computed tomography angiography (CCTA) to reduce patients’ heart rates (HR) was investigated in the current work. Sixty patients who received CCTA to exclude coronary artery disease were included in our study and separated into two groups: with biofeedback (W-BF) and without biofeedback (WO-BF). The W-BF group used a biofeedback device for 15 min before CCTA. HR was determined in each patient at four measurement time points (MTP): during the pre-examination interview (MTP1), positioning on the CT patient table before CCTA (MTP2), during CCTA image acquisition (MTP3), and after completing CCTA (MTP4). If necessary, beta-blockers were administered in both groups after MTP2 until a HR of less than 65 bpm was achieved. Two board-certified radiologists subsequently assessed the image quality and analyzed the findings. Overall, the need for beta-blockers was significantly lower in patients in the W-BF group than the WO-BF group (p = 0.032). In patients with a HR of 81–90, beta-blockers were not required in four of six cases in the W-BF group, whereas in the WO-BF group all patients needed beta-blockers (p = 0.03). The amount of HR reduction between MTP1 and MTP2 was significantly higher in the W-BF compared to the WO-BF group (p = 0.028). There was no significant difference between the W-BF and WO-BF groups regarding image quality (p = 0.179). By using biofeedback prior to elective CCTA, beta-blocker use could be decreased without compromising CT image quality and analysis, especially in patients with an initial HR of 81–90 bpm.

Abstract Image

查看原文本刊更多论文

选择性CT冠状动脉造影前使用心率变异性生物反馈降低心率的临床价值和对β受体阻滞剂的需求。

目前的工作是研究选择性冠状动脉计算机断层摄影血管造影术（CCTA）前生物反馈对降低患者心率（HR）的价值。60名接受CCTA以排除冠状动脉疾病的患者被纳入我们的研究，并被分为两组：有生物反馈（W-BF）和无生物反馈（WO-BF）。W-BF组在CCTA前使用生物反馈装置15分钟。在四个测量时间点（MTP）测定每位患者的HR：在检查前面谈（MTP1）期间，在CCTA之前（MTP2）、在CCTA图像采集期间（MTP3）和完成CCTA之后（MTP4）在CT患者台上定位。如有必要，在MTP2后，两组均给予β受体阻滞剂，直至心率低于65 bpm。两名委员会认证的放射科医生随后评估了图像质量并分析了结果。总体而言，W-BF组患者对β受体阻滞剂的需求显著低于WO-BF组（p = 0.032）。在HR为81-90的患者中，W-BF组的六个病例中有四个不需要β受体阻滞剂，而WO-BF组的所有患者都需要β受体阻断剂（p = 0.03）。与WO-BF组相比，W-BF组MTP1和MTP2之间的HR减少量显著更高（p = 0.028）。W-BF组和WO-BF组在图像质量方面没有显著差异（p = 0.179）。通过在选择性CCTA之前使用生物反馈，可以在不影响CT图像质量和分析的情况下减少β受体阻滞剂的使用，尤其是在初始HR为81-90 bpm的患者中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Applied Psychophysiology and Biofeedback PSYCHOLOGY, CLINICAL-

CiteScore

5.30

自引率

13.30%

发文量

期刊介绍： Applied Psychophysiology and Biofeedback is an international, interdisciplinary journal devoted to study of the interrelationship of physiological systems, cognition, social and environmental parameters, and health. Priority is given to original research, basic and applied, which contributes to the theory, practice, and evaluation of applied psychophysiology and biofeedback. Submissions are also welcomed for consideration in several additional sections that appear in the journal. They consist of conceptual and theoretical articles; evaluative reviews; the Clinical Forum, which includes separate categories for innovative case studies, clinical replication series, extended treatment protocols, and clinical notes and observations; the Discussion Forum, which includes a series of papers centered around a topic of importance to the field; Innovations in Instrumentation; Letters to the Editor, commenting on issues raised in articles previously published in the journal; and select book reviews. Applied Psychophysiology and Biofeedback is the official publication of the Association for Applied Psychophysiology and Biofeedback.